Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Abstract

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• St. Michael's Hospital CA
• Université Paris Cité FR
• Harvard University US
• Assistance Publique – Hôpitaux de Paris FR
• Sorbonne Université FR
• Yale University US
• University of Toronto CA
• Wroclaw Medical University PL
• Duke University US
• State University of New York US
• Karolinska Institutet SE
• SUNY Downstate Health Sciences University US
• St Michael’s Hospital IE
• Inserm FR
• Clinical Research Institute US
• Hôpital Paris Saint-Joseph FR
• Georgetown University US
• University of Michigan US
• Hôpital Bichat-Claude-Bernard FR
• St Michaels Hospital GB
• The University of Texas Southwestern Medical Center US
• Vanderbilt University US
• University of Brescia IT
• Oregon Health & Science University US
• Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia IT
• University of Colorado Anschutz Medical Campus US
• Parkland Health & Hospital System US
• Lexicon Pharmaceuticals (United States) US

Related Publications